Literature DB >> 24643620

Adjuvant antifungal therapy after pulmonary surgery for aspergilloma: is it useful?

Lotfi Benhamed1, Didier Woelffle2.   

Abstract

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether adjuvant antifungal therapy is useful after pulmonary surgery for aspergilloma. One hundred and sixteen papers were identified using the search described below, of which 5 papers presented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. No paper was greater than level-three evidence. One study compared the outcomes of 72 patients treated for pulmonary aspergilloma (PA) during a 23-year period. Despite no difference being found in outcomes, more complications were seen in the surgery-alone group. Another study included 14 patients treated with amphotericin B alone or with flucytocine. They found no benefit in the treatment of PA by systemic antifungal therapy. One retrospective study reported complete eradication of PA in patients treated with preoperative and postoperative oral itraconazole. One large cohort study reported their outcomes in 256 patients with PA, divided into two groups: Group A (simple aspergilloma, n = 96) and Group B (complex aspergilloma, n = 160) after aggressive surgical treatment and antifungal therapy. They found no difference in the postoperative morbidity between two groups (P = 0.27). A postoperative fungal relapse was found in 2 patients. One retrospective study reported the outcomes and mortality in 61 cases with PA. Thirty-five (60%) patients were treated with antifungal agents, and 15 (25%) patients were treated surgically. Many cases did not respond to antifungal therapy. Nineteen (31%) patients died. We did not find evidence to support the role of adjuvant antifungal therapy following definitive surgical removal of the fungus ball in immunocompetent patients; however, randomized control studies in multiple centres, with new antifungal therapy, are necessary to confirm these preliminary results.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Antifungal chemotherapy; Aspergilloma; Thoracic surgery

Mesh:

Substances:

Year:  2014        PMID: 24643620     DOI: 10.1093/icvts/ivu069

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  The fate of aspergilloma patients after surgical treatment-experience from 22 cases.

Authors:  Katriina Pihlajamaa; Veli-Jukka Anttila; Jari V Räsänen; Juha T Kauppi; Ulla Hodgson
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

2.  Is adjuvant antifungal therapy after video-assisted thoracic surgery for pulmonary aspergilloma necessary?

Authors:  Shuo Zheng; Xin Li; Bin Hu; Hui Li
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

3.  Complex Pulmonary Aspergilloma: Surgical Challenges in a Third World Setting.

Authors:  Bernadette Ngo Nonga; Guy Aristide Bang; Bonaventure Jemea; Eric Savom; Perfura Yone; Ngahane Mbatchou; Jean Jacques Ze
Journal:  Surg Res Pract       Date:  2018-01-14

Review 4.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

5.  Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study.

Authors:  ChangMing Shen; GaoFeng Qiao; Cheng Wang; Feng Jin; YunZeng Zhang
Journal:  BMC Pulm Med       Date:  2022-01-19       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.